Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

Table 2

Phenotype of harvest product.

FG #	Total harvest ×10^9	% viability	%CD3 harvest	%CD4 harvest	%CD8 harvest
1	35	95	89	58	34
2	38	95	93	75	22
3	48.6	91	99	50	50
4	65.4	87	79	19	60
5	139	94	89	61	35
6	171	87	90	78	16